There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > IL-6


IL-6 Molecule Information

Target Synonym:IL6;Hybridoma growth factor;BSF-2;IFNB2;CTL differentiation factor;Interferon beta-2;IL-6;CDF;Interleukin-6;B-cell stimulatory factor 2;IFN-beta-2
Number of Launched Drugs:5
Number of Drugs in Clinical Trials:30
Lastest Research Phase:Approved

IL-6 Protein Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
Cat. No. Species Product Description Structure Purity Feature
IL6-M5245 Mouse Mouse IL-6 Protein, His Tag
IL6-H8218 Human Biotinylated Human IL-6 Protein, epitope tag free, ultra sensitivity (primary amine labeling)
IL6-H4218 Human ActiveMax® Human IL-6 Protein, Tag Free

IL-6 Part of Bioactivity data

IL6-H8218-Cell-based assay
Human FcRn Heterodimer Protein Cell_Base

Biotinylated Human IL-6, epitope tag free, primary amine labeling (Cat. No. IL6-H8218) stimulates proliferation of TF-1 human erythroleukemic cell line. The EC50 for this effect is 0.2532-0.4489 ng/mL (Routinely tested).

IL6-H4218-Cell-based assay
Human FcRn Heterodimer Protein Cell_Base

ActiveMax® Human IL-6, Tag Free (Cat. No. IL6-H4218) stimulates proliferation of TF-1 human erythroleukemic cell line. The EC50 for this effect is 0.2856-0.3636 ng/mL (Routinely tested).


Loaded Biotinylated Human IL-6, epitope tag free, primary amine labeling (Cat. No. IL6-H8218) on SA Biosensor, can bind Human IL-6 R alpha, His Tag (Cat. No. ILR-H4223) with an affinity constant of 45.9 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).


Loaded Human IL-6 R alpha, Fc Tag (Cat. No. ILR-H5259) on Protein A Biosensor, can bind ActiveMax® Human IL-6, Tag Free(Cat. No. IL6-H4218) with an affinity constant of 35.9 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

IL-6 Molecule Synonym Name


IL-6 Molecule Background

Interleukin 6 (IL-6) is also known as HGF, BSF2,HSF, IFNB2 and  IL-6, originally identified as a B cell differentiation factor, is a multifunctional cytokine that regulates immune responses, hematopoiesis, acute phase responses, and inflammatory reactions.It is secreted by T cells, macrophages , monocytes, fibroblasts,endothelial cells,et.al. to stimulate immune response to trauma, especially burns or other tissue damage leading to inflammation. Interleukin 6 has been shown to interact with interleukin-6 receptor  and glycoprotein. IL-6 is relevant to many disease processes such as diabetes,atherosclerosis, depression,Alzheimer's Disease,systemic,lupus erythematosus,prostate cancer and rheumatoid arthritis. Advanced/metastatic cancer patients have higher levels of IL-6 in their blood.Hence there is an interest in developing anti-IL-6 agents as therapy against many of these diseases.

IL-6 References

IL-6 Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Pomalidomide CC-4047; CDC-394; IMID-4047; IMiD-1 Approved Celgene POMALYST fda Multiple myeloma (MM) CELGENE 2013-02-08 Multiple myeloma (MM) Details
Luminol sodium MP-1032,MP1032 Approved Metrio, Selvim Psoriasis, Immunological disorders Details
Lenalidomide CDC-501; CC-5013; CDC-5013; ENMD-0997; IMID-5013; IMiD-3 Approved Celgene, BeiGene REVLIMID fda Myelodysplastic syndrome (MDS), Mantle cell lymphoma (MCL), Multiple myeloma (MM) CELGENE 2005-12-27 Myelodysplastic syndrome (MDS), Mantle cell lymphoma (MCL), Multiple myeloma (MM), Peripheral T cell lymphoma (PTCL) Details
Siltuximab CNTO-328; cCLB-8,CNTO328,cCLB8 Approved Janssen, EUSA Pharma SYLVANT fda Multicentric Castleman's Disease (MCD) JANSSEN BIOTECH 2014-04-23 Multicentric Castleman's Disease (MCD) Details
Thalidomide NSC-527179; NSC-66847; K-17,NSC527179; NSC66847; K17,NSC 527179; NSC 66847; K 17 Approved Celgene THALOMID fda Erythema nodosum leprosum (ENL), Multiple myeloma (MM) CELGENE 1998-07-16 Erythema nodosum leprosum (ENL), Multiple myeloma (MM) Details

IL-6 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Atiprimod dihydrochloride SK&F-106615-A2 Phase Ⅱ Genzyme, GlaxoSmithKline, Callisto Osteoarthritis (OA), Solid tumours, Multiple myeloma (MM), Rheumatoid arthritis (RA) Details
BLX-1002 BLX-1002 Phase Ⅱ Orchid Type 2 diabetes Details
Mycobacterium cell wall-DNA Complex (ProMetic Life Sciences) EN-3348 BLA Filing Prometic Life Sciences Bladder cancer Details
Clazakizumab ALD-518; ALD518-003; BMS-645429; BMS-945429 Phase Ⅲ Alder Biopharmaceuticals Psoriatic arthritis, Inflammation, Rheumatoid arthritis (RA), Rejection of renal transplantation Details
APX-007 (Apexigen/Epitomics) APX-007 Preclinical Epitomics, Apexigen Inflammation Details
MEDI-5117 MEDI-5117; WBP-216,WBP216; MEDI5117 Phase Ⅰ WuXi AppTec, MedImmune Rheumatoid arthritis (RA) Details
QR-449 QR-440; QR-443; QR-449 Phase Ⅰ ProPhase Labs Cachexia, Metabolic disorders, Pain Details
EBI-031 EBI-031,EBI031 Phase Ⅰ Sesen Bio, Roche Uveitis, Diabetic macular edema Details
Gerilimzumab ARGX-109; GB-224; RYI-008 Phase Ⅱ arGEN-X, Bird Rock Bio, Genor Biopharma Rheumatoid arthritis (RA) Details
Ziltivekimab COR-001,COR 001 Phase Ⅱ AstraZeneca, Corvidia Therapeutics Cardiovascular disorders, Chronic kidney disease Details
Anti-IL-6 mAb (Vaccinex) OPR-003; VX-30; mAb-1339 Phase Ⅰ Vaccinex, EUSA Pharma hematological malignancies, Rheumatoid arthritis (RA) Details
Elsilimomab (Orphan Pharma international) Phase Ⅱ AOP Orphan Pharmaceuticals, Orphan Pharma international Multiple myeloma (MM), Lymphoma Details
FM-101 (Femta Pharmaceuticals) FM-101 Preclinical Femta Pharmaceutical Multiple myeloma (MM), Rheumatoid arthritis (RA), Crohn's disease Details
Sirukumab BA-003;CNTO-136,BA003,CNTO136 BLA Filing GlaxoSmithKline, Janssen Rheumatoid arthritis (RA) Details
Y-25510 Y-25510 Phase Ⅰ Mitsubishi Tanabe Pharma Leucopenia, Thrombocytopenia Details
Interleukin-6 receptor (Tosoh) CD-126 Preclinical Tosoh Stem cell mobilization Details
FB-704A FB-704; FB-704A Phase Ⅰ Fountain BioPharma Rheumatoid arthritis (RA) Details
YS-IL6 YS-IL6; YSIL-6; YSIL6-O-RA; YSIL6-T-PS Phase Ⅱ Y's Therapeutics Rheumatoid arthritis (RA) Details
TA-383 TA-383 Phase Ⅱ Mitsubishi Tanabe Pharma Rheumatoid arthritis (RA) Details
KOB-03 KOB-03 Phase Ⅱ Dong Wha Pharmaceuticals Allergic rhinitis (AR) Details
ME-3738 ME-3738 Phase Ⅱ Meiji Seika Pharma HCV infection Details
Anti-interleukin-6 receptor monoclonal antibody (Biocad) Phase Ⅱ Biocad Autoimmune diseases Details
HL-2351 HL-2351; GX-P4; rhIL-1Ra-hyFc Phase Ⅱ Genexine, Handok Inc Rheumatic disorders, Cryopyrin-Associated Periodic Syndromes (CAPS) Details
Tocilizumab biosimilar (Mycenax Biotech) Phase Ⅰ Mycenax Biotech Rheumatoid arthritis (RA) Details
Olokizumab Anti-IL6-UCB; CDP-6038 Phase Ⅲ UCB, R-Pharm Rheumatoid arthritis (RA) Details
AMG-220 C-326; AMG-220 Phase Ⅰ Amgen Crohn's disease Details
Cis-urocanic acid UCA-001; UCA-002; Cis-UCA Phase Ⅱ Herantis Pharma Atopic dermatitis, Dry eye disease Details
PF-04236921 PF-04236921; PF-4236921 Phase Ⅱ Pfizer Crohn's disease Details
Wogonin Phase Ⅰ Daewoong, China Pharmaceutical University, Hefei Cosource Medicine Technology, Buchang Pharma Gastric cancer, Leukemia, Liver cancer Details
PXL-01 PXL-01 Phase Ⅲ ProMore Pharma, Technomark Life Sciences, PharmaResearch Products Post-surgical adhesions Details

This web search service is supported by Google Inc.